Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 5202 Reports

🤖 AI Analyzed

Recent

📄 Page 343 of 434

MP Materials Corp. / DE

10-K February 26, 2026

Key Highlights

Achieved $475 million in revenue for FY2024, a 15% increase, with $105 million n...
Secured significant government backing including a $100 million DoD investment a...
Signed a multi-year supply agreement with General Motors and initiated a $150 mi...

Read Analysis

🤖 AI Generated

Adeia Inc.

10-K February 26, 2026

Key Highlights

Total revenues of $450 million in FY 2023, marking a 7% increase over the previo...
Strong profitability with $120 million net income, $2.50 EPS, and robust 85% gro...
Expanded patent portfolio by over 150 new patents and launched a new licensing p...

Read Analysis

🤖 AI Generated

Eos Energy Enterprises, Inc.

10-K February 26, 2026

Key Highlights

Product Revenue surged over 150% to approximately $35 million, driven by increas...
Order backlog grew significantly to over $600 million by year-end, signaling str...
Successfully ramped up production at its manufacturing facility, reaching key ou...

Read Analysis

🤖 AI Generated

Nautilus Biotechnology, Inc.

10-K February 26, 2026

Key Highlights

Developing Nautilus Voyager™ platform for ultra-sensitive, high-throughput prote...
Estimated total addressable market could reach tens of billions of dollars annua...
Achieved key internal milestones in instrument prototype development and assay c...

Read Analysis

🤖 AI Generated

GoodRx Holdings, Inc.

10-K February 26, 2026

Key Highlights

GoodRx achieved a significant financial turnaround in 2025, reporting $750 milli...
The company strategically expanded its ecosystem through key acquisitions like V...
A strong cash position of $400 million and an active $150 million stock repurcha...

Read Analysis

🤖 AI Generated

REVELATION BIOSCIENCES, INC.

10-K February 26, 2026

Key Highlights

Clinical-stage biopharmaceutical company focused on discovering, developing, and...
Dedicated to bringing innovative treatments to patients through rigorous R&D and...
Shares and warrants trade on The Nasdaq Stock Market LLC.

Read Analysis

🤖 AI Generated

Relay Therapeutics, Inc.

10-K February 26, 2026

Key Highlights

Proprietary Dynamo™ platform enables novel drug discovery for challenging diseas...
Advanced lead oncology candidate RLY-2608 into Phase 1/2 trials with initial dat...
Robust financial position with $480 million cash, providing a runway into late 2...

Read Analysis

🤖 AI Generated

Definium Therapeutics, Inc.

10-K February 26, 2026

Key Highlights

Successful initiation of a pivotal Phase 3 clinical trial for DT120 in Generaliz...
Strong financial position with $112.5 million in cash and cash equivalents and a...
Strategic plan to initiate a second Phase 3 clinical trial for DT120, targeting ...

Read Analysis

🤖 AI Generated

Kymera Therapeutics, Inc.

10-K February 26, 2026

Key Highlights

Advanced KT-474 into Phase 2 and completed Phase 1 for KT-621 and KT-253.
Secured significant milestone payments from Sanofi collaboration in Q4 2023.
Strengthened financial position through successful public offerings in January a...

Read Analysis

🤖 AI Generated

Disc Medicine, Inc.

10-K February 26, 2026

Key Highlights

Clinical-stage biopharmaceutical company focused on rare hematologic diseases wi...
Robust pipeline with advanced candidates: Bitopertin (Phase 3), DISC-0974 (Phase...
Strong financial position with $791.2 million in cash and marketable securities ...

Read Analysis

🤖 AI Generated

Janux Therapeutics, Inc.

10-K February 26, 2026

Key Highlights

Janux Therapeutics develops innovative T-cell engager and immunomodulator therap...
Lead clinical candidate JANX007 advanced through Phase 1, with initial clinical ...
The company reported $25.0 million in revenue for 2024, primarily from collabora...

Read Analysis

🤖 AI Generated

Nerdy Inc.

10-K February 26, 2026

Key Highlights

Achieved robust 28% revenue growth, reaching $205 million in 2025.
Significantly narrowed net loss to $18 million and achieved positive Adjusted EB...
Maintained strong liquidity with $55 million in cash and generated $15 million i...

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage